This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Tacrolimus leukoencephalopathy has well documented clinical and neuroradiologic features.1 The latter suggest endothelial dysfunction as the underlying etiology.2 Confirmatory neuropathologic data have been lacking.
Case reports.
A 40-year-old woman with biopsy-proven acute rejection was admitted 3 weeks after an orthotopic liver transplant for alcoholic cirrhosis. Alanine aminotransferase was elevated at 226 IU/L (<50 IU/L). She also had elevated cholesterol levels (237–411 IU/L) and was hypertensive (approximately 160/90). Erythrocytes showed anisocytosis and poikilocytosis (spiculated, fragmented, and targets). Tacrolimus 4 mg BID had been started the day after transplantation.
The patient had 2 days of toxic tacrolimus levels of 25 ng/mL and 29 ng/mL (>20 ng/mL), followed 4 days later by new onset seizures and mental status changes (lethargy to agitation). BP just after the seizure was 172/104. The last reading prior to her seizure was 144/88. MRI revealed two large white matter lesions in the right frontal lobe without mass effect (figure 1A). There was minimal peripheral enhancement, as well as scattered white matter lesions in the frontal and parieto-occipital lobes bilaterally (figure 1B). Her condition continued to deteriorate over the next 2 days with increasing seizure activity culminating in unresponsiveness. Brain biopsy was performed to exclude a treatable infectious process. Her platelet count at this time was 329,000/μL (445,000/μL upon admission); her prothrombin time and partial thromboplastin time were normal. However, that same day bleeding at the biopsy site …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
